Back to Search Start Over

Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals

Authors :
Mary L. Phillips
Thomas J. Carmody
Phillip Adams
Crystal Cooper
Thilo Deckersbach
Marisa Toups
Melvin G. McInnis
Madhukar H. Trivedi
Haris Aslam
Myrna M. Weissman
Henry W. Chase
Scott Peltier
Tsafrir Greenberg
Maria A. Oquendo
Jorge R. C. Almeida
Benji T. Kurian
Maurizio Fava
Jay C. Fournier
Ramin V. Parsey
Patrick J. McGrath
Richelle Stiffler
Source :
Molecular psychiatry
Publication Year :
2019

Abstract

Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. 222 unmedicated adults with MDD randomized to receive sertraline (n=110) or placebo (n=112) in the EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care) study completed demographic and clinical assessments, and pre-treatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on Week-8 depression levels (Fs≥9.67,ps≤0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower Week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pre-treatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pre-treatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment. Trial Registration: NCT01407094; http://clinicaltrials.gov/show/NCT01407094

Details

Language :
English
ISSN :
14765578 and 13594184
Volume :
25
Issue :
7
Database :
OpenAIRE
Journal :
Molecular psychiatry
Accession number :
edsair.doi.dedup.....dfe8079d61339c11f0e2a358320574d0